How to Evaluate AI Vendors for Healthcare

Introduction

Physicians now use artificial intelligence far more than most hospital boards realize, and adoption is outrunning the procurement habits that were built for ordinary software. The American Medical Association reports that 81% of physicians use AI in their practices, up from 38% in 2023. That growth means vendor decisions are being made inside nearly every clinical setting, often without a shared method for judging what is being bought. Learning how to evaluate AI vendors for healthcare has therefore become a core skill for chief medical officers, compliance leads, security teams, and the clinicians who live with the results. A weak evaluation can put an inaccurate model in front of patients, expose protected health information, or lock a health system into a contract it cannot exit. A disciplined evaluation does the opposite by turning vague demo promises into evidence that can be tested, scored, and written into a contract. This guide walks through the full process, from scoping the clinical need to monitoring a live model, and it builds on our broader work on assessing AI vendor partnerships.

Quick Answers on Evaluating AI Vendors for Healthcare

What is the first step in evaluating AI vendors for healthcare?

Learning how to evaluate AI vendors for healthcare starts with defining the clinical problem and success metric before any demo. Then screen vendors on regulatory status, clinical evidence, privacy controls, bias testing, integration fit, and contract terms.

Does a HIPAA claim prove a healthcare AI vendor is safe?

No. No federal HIPAA certification exists, so “HIPAA compliant” is a self-assessment. Verify a signed business associate agreement, the full subcontractor chain, security audits, and whether your patient data can train the vendor’s models.

How do you validate a healthcare AI vendor’s accuracy claims?

Ask for peer-reviewed or independent results on the healthcare AI product, then run a local pilot on your own patients. Measure sensitivity, positive predictive value, alert burden, and subgroup performance before signing a long-term agreement.

Key Takeaways

• Define the clinical problem, the workflow owner, and a measurable success metric before any vendor demonstration begins.
• Treat vendor accuracy claims as hypotheses, and test them with a local pilot on your own patients and subgroups.
• A signed business associate agreement is necessary but not sufficient, so review data-use, subcontractor, and model-training terms together.
• Negotiate audit rights, retraining notice, liability carve-outs, and an exit plan before the contract is signed, not after.

Understanding How to Evaluate AI Vendors for Healthcare

Learning how to evaluate AI vendors for healthcare means testing a supplier’s clinical evidence, regulatory status, privacy controls, bias results, integration fit, and contract terms before purchase, then monitoring real-world performance afterward.

Why Healthcare AI Carries Different Risk Than Ordinary Software

Most software fails loudly, with an error message or a crashed screen, while a clinical AI model usually fails quietly by producing a plausible but wrong answer. That difference is the reason a standard IT procurement checklist falls short when the product influences diagnosis, triage, documentation, or billing. The wider landscape of artificial intelligence in healthcare now spans imaging, ambient scribes, sepsis alerts, coding assistants, and patient messaging, and each category carries its own failure pattern. A buyer who treats all of them as interchangeable software subscriptions will overlook the questions that matter most. Clinical risk also compounds quickly, because a single flawed model can touch thousands of patients before anyone spots the pattern.

The sharpest warning for buyers is that a model can look excellent in a vendor deck and still perform poorly in your hospital. An external validation of the Epic sepsis model at Michigan Medicine covered 38,455 hospitalizations in a JAMA Internal Medicine study. It found an area under the curve of 0.63 and a sensitivity of only 33%. The tool also generated alerts for 18% of all patients, which created a heavy review burden for clinicians. Developers had reported stronger figures, so the gap between published claims and local reality was large. The lesson is that performance depends on the population, the workflow, and the data feeding the model, not on the brand name of the vendor.

Healthcare AI also changes after purchase in ways that conventional software does not. Models drift as patient mix, coding practices, and clinical protocols shift, and vendors may retrain or reweight a model without the customer noticing. Responsibility does not move to the vendor when something goes wrong, because the hospital still owns the clinical decision, the patient relationship, and the regulatory exposure. Boards that understand this early tend to ask for monitoring rights, performance guarantees, and named accountable owners from the first conversation. Those requests are far easier to win before a purchase order exists than after a go-live date has created pressure to sign.

Mapping Clinical Needs Before Any Vendor Demo

Building on that risk picture, the most reliable evaluations begin with a written problem statement rather than a vendor shortlist. A demo is designed to make a product look useful, so teams that attend demos first often end up shaping their needs around whatever the loudest vendor can show. Start instead by naming the clinical or operational problem, the people affected, the current baseline, and the number that would count as success. The NHS guidance on buying AI in health and care makes the same point by asking buyers to justify why AI is the right tool before they assess any product. Skipping this step is the most common reason pilots end with an unclear verdict and no agreed basis for deciding.

A good problem statement names one workflow, one owner, and one measurable outcome. For example, a team might aim to cut physician documentation time by 30 minutes per clinic day, or to raise early sepsis detection without increasing alert fatigue. Next, confirm that the data needed to run and evaluate the product actually exists in usable form, using a structure such as an AI data readiness assessment framework. Many promising pilots stall because the vendor assumed clean, coded, interoperable data and the hospital could not supply it. Capturing a pre-deployment baseline also gives you something honest to compare against when the vendor later claims a return on investment.

Reading Clinical Evidence and Validation Claims

Moving on to proof, the next job is to separate real evidence from marketing language. Vendors often cite internal studies, retrospective datasets, or accuracy figures with no confidence intervals, and these numbers rarely describe how the model will behave on your patients. Ask for the exact study design, the population studied, the reference standard, the time period, and whether the data came from sites similar to yours. Peer-reviewed publication is a strong signal, although a published study from one academic center does not guarantee results in a community hospital with different demographics and equipment. Treat every figure without a stated sample size as unverified until the vendor provides supporting detail.

Metrics deserve careful reading because a single headline number hides trade-offs. Sensitivity tells you how many true cases the model catches, while positive predictive value tells you how many alerts are correct, and both change with disease prevalence in your setting. A model with a respectable area under the curve can still bury clinicians in false alarms if prevalence is low and the alert threshold is set aggressively. Request performance broken out by age, sex, race, language, and care setting, because averages can conceal serious failures for specific groups. If the vendor cannot supply subgroup results, treat that absence as a finding rather than an oversight.

The strongest evidence a vendor can offer is a willingness to let you validate the model locally before you commit. Joint guidance from the Coalition for Health AI and the Joint Commission tells health systems to ask how vendors validated their AI and whether local validation is possible. A silent-mode pilot, where the model scores real patients but its outputs are hidden from clinicians, is a safe way to compare predictions against outcomes. This approach echoes broader work on AI precision in healthcare decisions, where thresholds and workflows matter as much as the algorithm. Vendors that resist silent-mode testing, refuse to share validation methods, or insist that results are proprietary deserve a lower score on the evidence criterion.

Finally, ask how the vendor handles model updates after approval of your pilot results. A model that performs well in March can behave differently in September if the vendor swaps a foundation model, changes training data, or adjusts thresholds. Request a written change-management policy that defines what counts as a material change, how much notice you receive, and whether you can re-run your validation before updates reach production. Ask whether the vendor keeps version histories so that any prediction can be traced to the exact model that produced it. These controls matter most for generative systems, where small prompt or model changes can alter output style and accuracy in ways that are difficult to notice.

Regulatory Status, FDA Pathways, and Marketing Claims

Shifting from evidence to oversight, buyers need to know whether a product is regulated as a medical device and whether the vendor’s claims match its authorization. Software that diagnoses, treats, or drives clinical decisions may fall under FDA oversight as software as a medical device, while administrative tools often do not. Confirming this early prevents a late-stage surprise when legal review discovers that the product needs authorization it does not have. The agency maintains a public list of AI-enabled medical devices that buyers can search to confirm a clearance, its date, and its review pathway. Radiology dominates that list, so imaging buyers will find more precedent than buyers of documentation or patient-messaging tools.

Clearance describes a specific intended use, and a vendor that markets beyond that use is creating risk for you. Read the indications for use carefully, because a tool cleared to flag a finding for a radiologist is not cleared to make an autonomous diagnosis. Compare the sales deck, the website, and the contract language against the authorization letter, and ask the vendor to explain any gap in writing. Our overview of FDA regulation of AI healthcare tools explains how clearances, approvals, and exemptions differ. Many clinical decision support products sit in gray areas, so ask for the vendor’s regulatory analysis rather than accepting a verbal assurance.

Marketing claims deserve the same scrutiny as regulatory ones, and enforcement shows that regulators are paying attention. The Texas Attorney General settled with Pieces Technologies after finding its advertised severe hallucination rate, fewer than one per 100,000, was likely inaccurate and may have misled hospitals. That outcome does not mean every vendor exaggerates, but it does mean buyers should demand the methodology behind any error-rate figure. Ask how the metric was defined, who measured it, on what sample, and whether an independent party can reproduce it. If the answers are vague, discount the claim to zero and rely on your own testing.

Privacy, HIPAA, and the Business Associate Chain

Turning to data protection, the first thing to understand is that vendors cannot be certified as HIPAA compliant by any federal body. Law firm analysis from Fisher Phillips on vendors that overstate compliance notes that there is no federal HIPAA certification, seal, or registry. A vendor describing itself as compliant is making a self-assessment, and the Federal Trade Commission can treat such claims as potentially deceptive. Your job is to verify the underlying controls rather than accept the label, starting with the business associate agreement and the security documentation that supports it. Treat any such label as a starting question rather than an answer.

A business associate agreement is the floor of a privacy review, and it cannot fix a contract that quietly grants the vendor broad data rights. Read the agreement together with the commercial terms, because a vendor’s standard terms of service can conflict with the agreement and create exposure. Confirm whether patient data may be used to train or improve the vendor’s models, and require a clear written answer rather than language about improving services. Ask how the vendor de-identifies data, whether it uses Safe Harbor or Expert Determination, and who certified the method. Our guide to data privacy and security in healthcare AI covers the underlying safeguards in more detail.

The chain of subcontractors is where many reviews fall apart, because AI features frequently depend on third-party language model providers and cloud services. Each downstream party that touches protected health information needs its own business associate agreement, and the vendor should be able to show an unbroken chain on request. Ask for a current list of subprocessors, the countries where data is stored and processed, and the process for notifying you when that list changes. Also confirm retention and deletion terms, since leftover prompts, logs, and embeddings can hold sensitive details long after a contract ends. A vendor that handles these questions confidently and in writing has usually done the work, while evasive answers often signal gaps.

Bias, Fairness, and Ethics in Clinical Models

Beyond privacy, ethical risk shows up in who benefits from a model and who is quietly left behind. A widely cited study of a commercial population health algorithm found that it used health costs as a proxy for health needs. Researchers at Berkeley reported that this design cut the number of Black patients flagged for extra care by more than half. Less money had been spent on Black patients with the same level of need, so the algorithm rated them as healthier than equally sick White patients. The bias came from a reasonable-sounding design choice, not from malicious intent, which is exactly why buyers must test for it. Reformulating the target variable removed the disparity, which shows that vendor decisions about labels and proxies directly shape equity.

Fairness should be a scored procurement criterion with a defined test, not a values statement in the vendor’s brochure. Ask what populations the training and validation data represent, how subgroup performance was measured, and what the vendor did when it found gaps. Then repeat the analysis on your own patients during the pilot, comparing error rates across the groups you serve. Our overview of ethical concerns in healthcare AI outlines further questions on consent, transparency, and clinician autonomy. Disclosure matters too, because patients and clinicians deserve to know when AI contributes to a recommendation and what its known limits are.

Security Posture and Third-Party Model Dependencies

Stepping back from privacy law to technical safeguards, the security review should confirm that the vendor protects data in transit, at rest, and during model inference. Ask for recent independent assessments such as SOC 2 Type II reports, penetration test summaries, and, where relevant, HITRUST certification. The IAPP’s list of questions for health tech AI vendors notes that not all HITRUST certifications are equal and that the r2 assessment is widely considered the gold standard. Certifications are useful signals, but they describe the vendor’s environment in general rather than your specific deployment. A deployment-specific risk analysis is still your responsibility under the HIPAA Security Rule, so request architecture diagrams and data flow maps that show exactly where your information travels.

Modern clinical AI products are rarely built from scratch, which means your risk includes every model provider and cloud service behind the vendor. Ask which foundation models power the product, whether prompts and outputs are retained by those providers, and whether zero-retention terms apply. Confirm how the vendor defends against prompt injection, data leakage between customers, and unauthorized access to model weights or logs. Request a documented incident response plan with breach notification timelines that meet or beat your own obligations. Your governance committee, ideally structured along the lines of our guide to setting up an AI governance board, should review these answers before any contract moves forward.

Access control and auditability complete the security picture for any clinical AI product. Clinical AI tools should support role-based access, single sign-on, multi-factor authentication, and detailed logs showing who viewed or changed what. Ask whether output logs are detailed enough to reconstruct an individual prediction, because that record becomes essential when a clinician or patient questions a recommendation. Verify that the vendor tests its own systems regularly, fixes vulnerabilities on a documented schedule, and shares summary results with customers. Weak answers in this area rarely improve after signing, because the vendor has little incentive to invest once the contract is in place.

Implementation Realities: Integration, Workflow Fit, and Total Cost

Looking at what happens after procurement, even a clinically sound model fails if it does not fit the way people work. Integration with the electronic health record is the first test, because a tool that forces clinicians to open another window or retype data will be ignored. Ask which standards the product supports, such as FHIR and HL7 interfaces, how it handles single sign-on, and who builds and maintains each connection. Request a reference customer running the same EHR version and a similar workflow, and speak with them directly rather than relying on a curated testimonial. Our overview of AI in healthcare documentation shows how much workflow design shapes the outcome of otherwise capable tools.

Workflow fit is best judged by the clinicians who will use the product every day, not by the executives who approve the budget. Include frontline nurses, physicians, coders, and administrators in demonstrations, and give them a structured form for scoring usability and trust. Ask how the vendor explains its outputs, since clinicians rely more readily on recommendations when they can see the reasons. This idea connects directly to the core principles of explainable AI. Watch for alert fatigue, extra clicks, and unclear ownership of follow-up actions. Plan training, super-user support, and a feedback channel before go-live rather than after complaints begin to accumulate.

Total cost of ownership extends far beyond the subscription price. Include integration labor, data preparation, security review, legal review, clinician training time, ongoing monitoring effort, and the cost of any parallel workflow during the transition. Ask for pricing on volume tiers, additional modules, API usage, and renewal increases, since generative products often meter usage in ways that surprise finance teams. Compare the total against the measurable benefit defined in your problem statement, such as hours saved, denials reduced, or outcomes improved. If the business case only works under the vendor’s most optimistic assumptions, the product is probably not ready for your environment.

Finally, assess the vendor’s ability to support you over time. Ask about customer support hours, escalation paths, uptime commitments, roadmap transparency, and the size of the clinical and engineering teams behind the product. Financial stability matters as well, since a startup that runs out of funding can leave you with an unsupported tool embedded in clinical work. Request references from customers who have used the product for at least a year, and ask what changed after the initial excitement faded. These conversations frequently reveal practical issues that no demo or questionnaire will surface.

Contracts, Liability, and Exit Rights

Moving on to the agreement itself, contract terms decide who pays when a model fails, so they deserve as much attention as the clinical evidence. A due diligence checklist from Promise Legal on clinical AI vendor contracts warns that standard liability caps are generally inadequate for clinical AI risk. Those caps are often tied to only one to twelve months of fees. It recommends indemnification covering claims from the vendor’s model outputs, regulatory penalties tied to the vendor’s conduct, and breach response costs from vendor-side failures. It also urges buyers to push back on blanket as-is disclaimers and to seek a minimum performance warranty tied to the vendor’s published accuracy benchmarks. Have counsel who understands health data and medical device law review every clause rather than relying on a generic procurement template.

The most valuable clauses are the ones that keep your options open, including audit rights, change notice, and a clean exit. Require the right to audit post-deployment performance on your own patients, and written notice, ideally 30 days, before material retraining or threshold changes. Specify data ownership, forbid training on protected health information unless explicitly agreed, and require deletion within a defined period after termination, with certification. Plan for portability, because dependence on one vendor’s proprietary formats creates the kind of vendor lock-in and switching costs that weaken every future negotiation. Insurance requirements, including cyber liability and technology errors and omissions coverage, should name your organization as an additional insured.

The Future of Healthcare AI Vendor Oversight

Looking ahead, vendor evaluation is likely to become more standardized as the industry builds shared tools for assurance. The Coalition for Health AI has proposed a nutrition label for health AI, a structured model card that would let buyers compare intended use, data sources, performance, and risks. Assurance labs that test models independently could reduce the burden on individual hospitals, particularly smaller ones that lack data science staff. Joint guidance from CHAI and the Joint Commission already points toward governance structures, local validation, and ongoing monitoring as baseline expectations. Buyers who build these habits now will find new standards easier to adopt than buyers who treat evaluation as a one-time purchasing event.

Continuous monitoring will replace the one-time procurement decision as the main basis of trust in clinical AI. Models will be re-evaluated on a schedule, performance dashboards will feed governance committees, and contracts will include triggers for suspension when metrics fall below agreed thresholds. Clinician voice will matter more as well, since the AMA survey found that 85% of physicians want to be consulted or directly involved in AI adoption decisions. Regulation will keep evolving at both federal and state levels, which makes contractual duties to cooperate on compliance changes increasingly valuable. Organizations that adopt responsible AI governance frameworks will be better placed to absorb that change without disruption.

Generative and agentic systems will stretch evaluation methods further because their outputs vary and their behavior depends on prompts, tools, and context. Buyers will need test sets built from their own documentation, scoring rubrics for accuracy and safety, and red-team exercises that probe for harmful or private outputs. Vendors that publish evaluation methods, share failure cases, and support customer-run testing will earn trust faster than those that guard every detail. None of this removes the need for human judgment, but it gives that judgment better evidence to work with. The practical advice is to start small, measure honestly, and expand only where the data supports it.

How to Evaluate AI Vendors for Healthcare Step by Step

In practice, the process below turns the earlier criteria into a repeatable workflow that a governance committee can run for every new tool. Treat each step as a gate, and do not advance a vendor to the next stage until the evidence for the current stage is documented. The steps move from problem definition through screening, scoring, piloting, contracting, and monitoring, and each produces an artifact you can file for audit. The code samples are illustrative templates that you can adapt to your own environment, tools, and policies. Keep the outputs together in a single vendor file so that reviewers, auditors, and future committees can see how the decision was made.

Step 1 - Define the problem and success metrics

Start with a 1-page charter that names the clinical or operational problem, the owner, the patient population, the baseline, and the target. A concrete baseline matters because most vendor claims are relative, and you need your own numbers to judge them. Include the harm you most want to avoid, such as missed diagnoses or biased triage, so that safety criteria appear next to benefit criteria. Pro tip: write the success metric before you meet any vendor, because it is much harder to stay objective after a persuasive demonstration. Store the charter where every reviewer can find it and require sign-off from the clinical owner.

use_case: "Early sepsis detection on adult inpatient units"
owner: "Chief Medical Informatics Officer"
population: "Adults admitted to medical and surgical wards"
baseline:
  time_to_antibiotics_minutes: 190
  alerts_per_100_patients: 6
target:
  time_to_antibiotics_minutes: 150
  max_alerts_per_100_patients: 8
  min_sensitivity: 0.80
safety_criteria:
  - "No degradation in subgroup sensitivity beyond 5 points"
  - "Clinician override always available"

Step 2 - Screen vendors against hard requirements

Before spending time on demonstrations, filter the market with pass or fail gates that apply to every candidate. The 5 typical gates are documented regulatory status, a willingness to sign a business associate agreement, a current security attestation, acceptance of local validation, and a full subprocessor list. Send the same written questionnaire to every vendor so that answers are comparable, and require responses from named people rather than a sales inbox. Compare each answer with public sources, such as the FDA device list, the vendor's published studies, and its security documentation. Pro tip: a vendor that declines a gate question in writing has still given you useful information, so record the refusal.

GATES = [
    "regulatory_status_documented",
    "baa_signed_or_accepted",
    "security_attestation_current",
    "local_validation_allowed",
    "subprocessor_list_provided",
]

def passes_gates(vendor: dict) -> bool:
    missing = [g for g in GATES if not vendor.get(g, False)]
    if missing:
        print(f"{vendor['name']} rejected: {', '.join(missing)}")
        return False
    return True

vendors = [
    {"name": "Vendor A", "regulatory_status_documented": True,
     "baa_signed_or_accepted": True, "security_attestation_current": True,
     "local_validation_allowed": True, "subprocessor_list_provided": True},
    {"name": "Vendor B", "regulatory_status_documented": True,
     "baa_signed_or_accepted": True, "security_attestation_current": False,
     "local_validation_allowed": False, "subprocessor_list_provided": True},
]
shortlist = [v for v in vendors if passes_gates(v)]

Step 3 - Score finalists with a weighted scorecard

Once 2 to 4 vendors pass the gates, score them with a weighted model that reflects your priorities. Typical categories include clinical evidence, safety and bias, privacy and security, integration, usability, contract terms, and cost. Weights should be agreed by the committee before scoring starts so that nobody adjusts them to favor a preferred vendor. Ask each reviewer to score independently, then discuss large disagreements, because those gaps often reveal hidden concerns about workflow or trust. Link the scorecard to your wider vendor partnership assessment practice so that results stay consistent across departments.

WEIGHTS = {
    "clinical_evidence": 0.25,
    "safety_and_bias": 0.20,
    "privacy_and_security": 0.20,
    "integration_and_usability": 0.15,
    "contract_terms": 0.10,
    "total_cost": 0.10,
}

def weighted_score(scores: dict) -> float:
    assert abs(sum(WEIGHTS.values()) - 1.0) < 1e-9
    return round(sum(WEIGHTS[k] * scores[k] for k in WEIGHTS), 2)

vendor_a = {"clinical_evidence": 4, "safety_and_bias": 3,
            "privacy_and_security": 5, "integration_and_usability": 4,
            "contract_terms": 3, "total_cost": 3}
print(weighted_score(vendor_a))  # scores range from 1 to 5

Step 4 - Run a silent-mode pilot and test for bias

A pilot on your own data is the most informative step in the whole process. Run the model in silent mode for 8 to 12 weeks, where it scores real cases but clinicians do not see the output, and compare its predictions with confirmed outcomes. Calculate sensitivity, positive predictive value, and alert volume overall and for each subgroup you serve, using the methods described in our guide to bias and fairness metrics. Our walkthrough on how to test models for fairness adds practical audit techniques. Pro tip: agree on pass thresholds before the pilot starts, so that results decide the outcome instead of enthusiasm.

Document every deviation, including data quality problems, missing fields, and cases the model could not score. These notes often matter as much as the headline metrics, because they show what the vendor will need to fix before a safe rollout. Share the findings with the vendor and give them a fair chance to respond, since some issues stem from integration mistakes rather than model weakness. If the results fall short of your thresholds, record the decision to stop or renegotiate, and keep the evidence for future reference. Treat the pilot report as a living document that the governance committee reviews before approving any expansion.

import pandas as pd

df = pd.read_csv("pilot_results.csv")  # columns: group, label, flagged

def summarize(g: pd.DataFrame) -> pd.Series:
    tp = ((g.label == 1) & (g.flagged == 1)).sum()
    fn = ((g.label == 1) & (g.flagged == 0)).sum()
    fp = ((g.label == 0) & (g.flagged == 1)).sum()
    return pd.Series({
        "n": len(g),
        "sensitivity": tp / (tp + fn) if (tp + fn) else float("nan"),
        "ppv": tp / (tp + fp) if (tp + fp) else float("nan"),
        "alert_rate": g.flagged.mean(),
    })

print(df.groupby("group").apply(summarize))
print(summarize(df))

Step 5 - Negotiate contract terms and exit rights

Convert what you learned into binding terms before any rollout begins. Use a checklist that covers 8 areas: data rights, model change notice, audit access, performance warranties, indemnity, insurance, subcontractors, and termination assistance. Counsel should compare the business associate agreement with the commercial agreement, since conflicts between them are a common source of exposure. Where the vendor refuses a term, document the risk and decide explicitly whether to accept it, mitigate it, or walk away. Pro tip: tie a portion of the fees to meeting agreed performance thresholds, which aligns incentives after go-live.

contract_checklist:
  data_rights:
    phi_model_training: "prohibited unless separately authorized"
    deletion_after_termination_days: 30
  change_management:
    notice_before_material_retraining_days: 30
    version_history_provided: true
  audit:
    local_performance_audit_rights: true
    prediction_level_logs: true
  liability:
    indemnity_for_model_output_claims: true
    cap_carve_outs: ["patient harm", "regulatory penalties", "data breach"]
  insurance: ["cyber liability", "technology E&O"]
  exit:
    data_export_format: "documented open formats"
    transition_assistance_days: 90

Step 6 - Monitor performance after go-live

Approval marks the beginning of oversight rather than the end of it. Set up a dashboard that tracks the same metrics you validated in the pilot, including subgroup performance, alert volume, override rates, and clinician feedback. Define thresholds that trigger review or suspension, and name the person who has authority to pause the tool. Review results at a regular governance meeting, and re-run validation whenever the vendor announces a material model change. Pro tip: schedule a 12-month re-evaluation of the vendor against the original scorecard, because needs, competitors, and regulations all shift over time.

THRESHOLDS = {"sensitivity": 0.75, "ppv": 0.30, "alert_rate": 0.10}

def monthly_check(metrics: dict) -> list:
    findings = []
    if metrics["sensitivity"] < THRESHOLDS["sensitivity"]:
        findings.append("Sensitivity below floor: open governance review")
    if metrics["ppv"] < THRESHOLDS["ppv"]:
        findings.append("PPV below floor: investigate alert burden")
    if metrics["alert_rate"] > THRESHOLDS["alert_rate"]:
        findings.append("Alert rate above ceiling: review threshold settings")
    return findings

print(monthly_check({"sensitivity": 0.71, "ppv": 0.34, "alert_rate": 0.12}))

Key Insights on Healthcare AI Vendor Selection

• Adoption has more than doubled, with 81% of physicians now using AI compared with 38% in 2023, so vendor selection decisions are already being made at scale.
• Physicians say 88% want robust safety and efficacy validation and 86% want strong data privacy before adopting AI, which gives buyers a ready-made list of evaluation priorities.
• An external check of a widely deployed sepsis model across 38,455 hospitalizations at Michigan Medicine found only 33% sensitivity and alerts on 18% of patients, far below reported expectations.
• A competing sepsis system monitored 590,736 patients across five hospitals and caught over 80% of cases with 38% alert precision, showing that strong local evidence is achievable.
• Fixing a cost proxy in one commercial risk algorithm could raise Black patients' share of care coordination enrollment from 17.7% to 46.5%, showing that design choices drive equity.
• A health system ambient scribe rollout reached 303,266 patient encounters in ten weeks and saved most users about an hour per day, though the figures were self-reported.
• Two ambient documentation pilots at Mass General Brigham and Emory reported a 21.2% absolute reduction in burnout at 84 days, with survey response rates as low as 11%.

The evidence points in one direction: performance claims only become trustworthy after they are tested on local patients, and benefits arrive when evaluation, workflow design, and monitoring work together. Physician adoption has accelerated sharply, yet the most demanding clinicians still ask first for validation and privacy protection. The sepsis comparison shows that two products with similar goals can differ enormously in sensitivity and alert burden. The bias example shows that a technically sound model can still produce unfair outcomes when its target variable is poorly chosen. The scribe and burnout results suggest real value for documentation tools, although self-reported data and enthusiastic pilot users call for careful interpretation. A buyer who combines these lessons will insist on local proof, subgroup analysis, and continuous monitoring before trusting any vendor claim.

Dimension	Weak evaluation	Strong evaluation	Evidence to request
Clinical evidence	Accepts vendor-supplied accuracy figures	Requires independent studies and a local silent-mode pilot	Study design, population, confidence intervals, subgroup results
Regulatory status	Relies on verbal assurances	Matches the indications for use to the planned deployment	FDA authorization letter or a written regulatory analysis
Privacy and HIPAA	Treats a compliance label as proof	Verifies the BAA, subprocessor chain, and model training rights	Signed BAA, subprocessor list, data flow map
Bias and fairness	Reviews overall accuracy only	Tests error rates by subgroup on local data	Subgroup metrics, training data description, remediation history
Security	Checks for a single certification	Reviews architecture, incident response, and model dependencies	SOC 2 Type II report, HITRUST r2, penetration test summary
Integration and workflow	Judges the polished demo	Scores usability with frontline clinicians	EHR interface specifications, reference customers
Contract and liability	Signs standard software terms	Negotiates indemnity, liability carve-outs, change notice, and exit	Draft clauses, insurance certificates, audit rights
Monitoring	Stops at go-live	Tracks drift, subgroup performance, and overrides monthly	Prediction logs, dashboards, version history
Transparency	Accepts black-box outputs	Requires explanations, model cards, and known limits	Model card, known failure summary
Total cost	Compares subscription prices	Includes integration, training, monitoring, and renewal terms	Itemized quote, renewal caps

Vendor Evaluation in Practice: Three Real Deployments

Turning to real deployments, the examples below show how health systems have applied evaluation principles, with both the gains and the shortcomings recorded. Each deployment illustrates a different criterion, including vendor selection standards, algorithm fairness, and head-to-head pilot design. The first shows how a large system chose an ambient documentation vendor. The second shows how an unexamined design choice created bias at national scale. The third shows how a two-vendor pilot produced comparative evidence. None of these stories is a perfect template, so read each one for the decision logic rather than the specific product. Together they demonstrate that disciplined evaluation does not slow innovation, because it replaces guesswork with evidence that clinicians and executives can trust.

Permanente Medical Group's Ambient Scribe Rollout

The Permanente Medical Group offered an ambient AI scribe to 10,000 physicians and staff across 21 Northern California locations. It had chosen the vendor on accuracy, ease of use, and privacy, including a commitment not to train the model on its patient data. In the first ten weeks, 3,442 physicians used the tool in 303,266 patient encounters, and most users saved about one hour per day at the computer. Staff received a one-hour webinar, trainers were available at every location, and patients were told about the tool and gave consent. The limitation is that a small percentage of notes contained hallucinations, such as a scheduled prostate exam recorded as performed. The time savings are also self-reported by the health system and its authors, and no comparison group was described. The lesson for buyers is that explicit selection criteria and structured training helped adoption, while note review remained necessary.

A Population Health Algorithm With a Hidden Cost Proxy

A commercial risk algorithm was used to select patients for care coordination programs, and industry estimates suggest tools of this kind evaluate roughly 200 million people a year. Researchers analyzed data on 6,079 Black patients and 43,539 White patients and found that the algorithm used health costs as a stand-in for medical need. Because Black patients typically receive fewer services, the cost measure understated their needs, and correcting the disparity could raise their enrollment share from 17.7% to 46.5% in the program. A revised model that combined health prediction with cost prediction reduced the measured bias by 84%. The drawback is that the problem was invisible in standard accuracy metrics, so buyers who tested only overall performance would have missed it. Bias still needs to be checked on local data, because a fix validated in one population does not automatically carry over to another.

Mass General Brigham's Two-Vendor Ambient Pilot

Mass General Brigham piloted a proof-of-concept in July 2023 with 18 physicians, tested two different ambient documentation technologies, and expanded to more than 800 providers by July 2024. Surveys of 873 clinicians at the system, together with 557 pilot users at Emory Healthcare, measured outcomes before and after adoption. Burnout prevalence fell by 21.2 percentage points at 84 days at Mass General Brigham, while Emory reported a 30.7% absolute increase in documentation-related well-being. The authors acknowledge important limits, including enthusiastic pilot participants and response rates of about 22% at Mass General Brigham and 11% at Emory. Some users also said the tools added time to note writing or worked less well for certain specialties. By April 2025 the program was available to all physicians, with more than 3,000 providers using the tools routinely.

Lessons From Three Healthcare AI Case Studies

Stepping back from successful rollouts, the case studies below examine what happens when evaluation fails or succeeds under scrutiny. Each case pairs a concrete problem with the solution that followed, the measurable result, and the controversy that remains. The first covers a sepsis model whose real-world performance disappointed. The second covers a marketing claim that drew a state enforcement action. The third covers a competing sepsis system with unusually strong published evidence. The common thread is that outcomes were determined by evidence quality rather than by vendor reputation. Buyers can use these stories as templates for the questions to ask before signing a contract.

Case Study: The Epic Sepsis Model at Michigan Medicine

Hospitals across the country had adopted a proprietary sepsis prediction model built into their electronic health record, yet little independent evidence existed on its performance. Michigan Medicine faced the problem of deciding whether to trust the tool, so researchers evaluated it on 38,455 hospitalizations between December 2018 and October 2019. The external validation found an area under the curve of 0.63, well below the 0.76 to 0.83 range that Epic and another health system had reported. The model had only 33% sensitivity, meaning it missed 67% of patients who developed sepsis. It also generated alerts for 18% of all hospitalized patients, which created a heavy review burden for clinicians. The practical solution for buyers is to treat embedded vendor figures as unproven until local data confirms them.

The positive predictive value of 12% implied that clinicians needed to evaluate roughly eight patients to find one true case. That ratio created alert fatigue risk without delivering reliable early detection of the patients who needed treatment. The controversy is that the vendor's reported figures and the independent figures diverged sharply, which raised concerns about internal validation. The independent study was conducted at a single academic center, so its limits include the possibility that results differ elsewhere. Even so, the finding gave other hospitals a concrete reason to run their own checks rather than trust a default configuration. Continuous monitoring of alert volume and missed cases remains the safeguard that catches this kind of gap after launch.

Case Study: Texas Attorney General and Pieces Technologies

Pieces Technologies, a Dallas-based company, sold generative AI products that summarized patient conditions and treatments for hospital staff. At least four major Texas hospitals sent patient data to the product in real time, so accuracy claims carried direct safety implications. The company advertised its products as highly accurate and claimed a severe hallucination rate below one per 100,000, which equals 0.001 percent. The challenge for the hospitals was that they had no independent way to confirm the figure before connecting live patient data. The Texas Attorney General investigated and found those metrics were likely inaccurate and may have misled hospitals about accuracy and safety.

The settlement requires the company to disclose accurately how accurate its products are. It also introduced a requirement that staff understand when they should or should not rely on the generative output. The state described the agreement as a first-of-its-kind healthcare generative AI settlement, which signals that unsupported performance claims can draw enforcement. The limitation is that a settlement sets obligations for one company rather than a standard for the whole industry. Buyers still carry responsibility for verifying the methodology behind any error-rate figure, including who measured it and on what sample.

Case Study: Bayesian Health's TREWS Sepsis System

The challenge was that sepsis alerts have long suffered from poor precision and low clinician response, so teams needed a system that caught cases early without overwhelming staff. Bayesian Health developed TREWS with the Johns Hopkins Machine Learning and Healthcare Lab, which began the work in 2015. The system was deployed across five hospitals in a two-year real-world study of 590,736 patients. It flagged 6,877 sepsis cases before antibiotics had begun and caught over 80% of sepsis cases. About 38% of evaluated alerts were confirmed as sepsis, compared with the 12% positive predictive value in the Michigan evaluation of a different model. Almost 90% of warnings were evaluated and more than half were checked within an hour, according to the published summary. Researchers say most systems see only 6 to 45% of alerts answered.

When an alert was confirmed within three hours, mortality was 18.7% lower than in cases not evaluated within that window. The limitation is that this result is an association rather than proof of causation. The authors acknowledge that busy or understaffed teams may have affected outcomes independently of the AI. Results from five hospitals also may not transfer to settings with different workflows or patient populations. The case still illustrates what strong evidence looks like when buyers ask for it. A large sample, multiple sites, reported sensitivity and precision, and measured clinician response all give a buyer something concrete to verify.

Common Questions About Evaluating AI Vendors for Healthcare